Table 2 Outcomes of clinical trials of BCMA-targeted therapies in MM from ASH 2024
From: BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting
References | [4] | [5] | [6] | [7] | [8] | [9] | [10] | [11] | |
|---|---|---|---|---|---|---|---|---|---|
Product | Belantamab mafodotin | Belantamab mafodotin | Belantamab mafodotin | Teclistamab | Teclistamab | Teclistamab | Cital-cel | Anito-cel | Anito-cel |
Clinical trial name | DREAMM-7 | DREAMM-8 | DREAMM-9 | MajesTEC-2 TRIMM-2 | MajesTEC-4/EMN30 | MajesTEC-5 | CARTITUDE-4 | NA | iMMagine-1 |
Research design | BVd vs. DVd | BPd vs. PVd | Belantamab mafodotin + VRd | teclisamab + DP | teclistamab + lenalidomide /teclistamab alone | teclistamab + DRd/teclistamab + DVRd | Cilta-cel vs. SoC | monotherapy | monotherapy |
Medium number of prior LOT | NA | 1 | 0 | 2 | NA | 0 | NA | 4 | 4 |
High-risk cytogenetics (%) | 28 | NA | NA | NA | NA | NA | NA | 29 | NA |
Phase | III | III | I | Ib | III | II | III | I | II |
Patients (n) | 243 vs. 251 | 82 vs. 77 | 108 | 27 | 94 | 49 | 208 vs. 211 | 38 | 58 |
ORR(%) | 90.0 | NA | 90.0 | 88.5 | NA | NA | NA | 100.0 | 95.0 |
CR(%) | 28.6 | 46.0 vs. 23.0 | NA | 61.5 | 100.0 | NA | 57.0 vs. 12.0 | 79.0 | 62.0 |
mFU(months) | 28.2 | 21.5 vs. 19.8 | NA | 25.8 | 14.4,5.0 and 4.9 | NA | 33.6 | 34.0 | 10.3 |
Survival(months) | mPFS: (36.6 vs. 13.4) mDOR: (35.6 vs. 17.8) | mPFS: (NR vs. 18.5) mDOR: (NR vs. 13.8) | NA | mPFS: 26.5 mDOR: NR | NA | NA | mPFS: NR vs. 37.8 mOS: NR vs. NR | NA | mPFS: NR mOS: NR |
MRD negativity(%) | 25.0 vs. 10.0 | 33.0 vs. 5.0 | VGPR+:10.0–83.0 CR+:0.0–75.0 | NA | 100.0 | 100.0 | 89.0 vs. 38.0 | 89.0 | 92.0 |
Grade ≥ 3 CRS(%) | NA | NA | NA | 0.0 | 0.0 | 0.0 | 0.0 | 3.0 | 2.0 |
Grade ≥ 3 ICANS(%) | NA | NA | NA | 0.0 | 0.0 | 0.0 | 0.0 | 5.0 | 2.0 |
Clinical trial identifier | NCT04246047 | NCT04484623 | NCT04091126 | NCT04722146 NCT04108195 | NCT04722146 | NCT05695508 | NCT04181827 | NCT04155749 | NCT05396885 |